Peripheral neuropathy exacerbation associated with topical 5-fluorouracil

Anti-Cancer Drugs

Volumn 17, Issue 9, 2006, Pages 1095-1098

  Wasif Saif, Muhammad ^a,f   Hashmi, Shahrukh ^b   Mattison, Lori ^c   Donovan, William B ^d   Diasio, Robert B ^e  

^a YALE CANCER CENTER   (United States)

^b GRIFFIN HOSPITAL   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d Diagnostic Clinic   (United States)

^e University of Alabama at Birmingham   (United States)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 flourouracil; Actinic keratosis; Capecitabine; Dihydropyrimidine dehydrogenase; Peripheral neuropathy; Polyneuropathy

Indexed keywords

ATORVASTATIN; DIHYDROPYRIMIDINE DEHYDROGENASE; ESOMEPRAZOLE; FLUOROURACIL; IMIQUIMOD; TRAZODONE;

ACTINIC KERATOSIS; AGED; ANAMNESIS; ARTICLE; CASE REPORT; DYSLIPIDEMIA; ENZYME ACTIVITY; ENZYME DEFICIENCY; ESOPHAGITIS; HUMAN; INSOMNIA; MALE; PAIN; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SENSORY NEUROPATHY; SKIN TOXICITY; TREATMENT WITHDRAWAL;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; DIHYDROURACIL DEHYDROGENASE (NADP); FLUOROURACIL; HUMANS; MALE; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 33749021332     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000231479.30524.0e     Document Type: Article

References (28)

1. Grem JL. Fluoropyrimidines. In: Chabner BA, Longo DL, editors. Cancer chemotherapy and biotherapy: principles and practice. 2nd ed. Philadelphia: Lippincott-Raven; 1996. pp. 149-211.
2. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 1989; 16:215-237.
3. Curran CF, Luce JK. Fluorouracil and palmar-plantar erythrodysesthesia. Ann Intern Med 1989; 111:858.
4. Saif MW, Quinn MG, Thomas RR, Ernst A, Grem JL. Cardiac toxicity associated with capecitabine therapy. Acta Oncol 2003; 42:342-344.
5. Riehl JL, Brown WJ. Acute cerebellar syndrome secondary to 5-fluorouracil therapy. Neurology 1964; 14:961-967.
6. Moertel CG, Reitemier RJ, Bolton CF, Shorter RG. Cerebellar ataxia associated with fluorinated pyrimidine therapy. Cancer Chemother Rep 1964; 41:15-18.
7. Lynch HT, Droszcz CP, Albano WA, Lynch JF. 'Organic brain syndrome' secondary to 5-fluorouracil toxicity. Dis Colon Rectum 1981; 24:130-131.
8. Stein ME, Drumea K, Yarnitsky D, Benny A, Tzuk-Shina T. A rare event of 5-fluorouracil-associated peripheral neuropathy: a report of two patients. Am J Clin Oncol 1998; 21:248-249.
9. Saif MW, Wilson RH, Harold N, Keith B, Dougherty DS, Grem JL. Peripheral neuropathy associated with weekly oral 5-fluorouracil, leucovorin and eniluracil. Anticancer Drugs 2001; 12:525-531.
10. Saif MW, Wood TE, McGee PJ, Diasio RB. Peripheral neuropathy associated with capecitabine. Anticancer Drugs 2004; 15:767-771.
11. Johnson MR, Hageboutros A, Wang K, High L, Smith JB, Diasio RB. Life threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res 1999; 5:2006-2011.
12. Johnson MR, Schwabe W, Haöusler P, Van Kuilenburg ABP, Van Gennip AH, Behnke D, Hoöffken K. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5 fluorouracil (5-FU)-related toxicity compared with controls. Clin Cancer Res 2001; 7:2832-2839.
13. Jury CS, Ramraka-Jones VS, Gudi V, Herd RM. A randomized trial of topical 5% 5-fluorouracil (Efudix cream) in the treatment of actinic keratoses comparing daily with weekly treatment. Br J Dermatol 2005; 153:808-810.
14. Johnson MR, Yan J, Shao L, Albin N, Diasio RB. Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity. J Chromatogr B Biomed Sci Appl 1997; 696:183-191.
15. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248-254.
16. Lu Z, Zhang R, Diasio RB. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 1993; 53:5433-5438.
17. Lu Z, Zhang R, Carpenter JT, Diasio RB. Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: implication for 5-fluorouracil-based chemotherapy. Clin Cancer Res 1998; 4:325-329.
18. 13C-uracil breath test. Clin Cancer Res 2004; 10:2652-2658.
19. Harris BE, Song R, Soong SJ, Diasio RB. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 1990; 50:197-201.
20. www.efudex.com.
21. Kopp HG, Moerike K, Kanz L, Hartmann JT. Leflunomide and peripheral neuropathy: a potential interaction between uracil/tegafur and leflunomide. Clin Pharmacol Ther 2005; 78:89-90.
22. Takimoto CH, Lu ZH, Zhang R, Liang MD, Larson LV, Cantilena LR Jr, et al. Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res 1996; 2:477-481.
23. Pirzada NA, Ali II, Dafer RM. Fluorouracil-induced neurotoxicity. Ann Pharmacother 2000; 34:35-38.
24. Johnson MR, Diasio RB. Importance of DPD deficiency in patient exhibiting toxicity following treatment with 5-fluorouracil. Adv Enzyme Regul 2001; 41:151-157.
25. Saif MW, Mattison L, Carollo T, Ezzeldin H, Diasio RB. Dihydropyrimidine dehydrogenase deficiency in an Indian population. Cancer Chemother Pharmacol 2006; 19:1-6.
26. Delval L, Klastersky J. Optic neuropathy in cancer patients. Report of a case possibly related to 5 fluorouracil toxicity and review of the literature. Am J Clin Oncol 1998; 21:248-249.
27. Okeda R, Shibutani M, Matsuo T, Kuroiwa T, Shimokawa R, Tajima T. Experimental neurotoxicity of 5-fluorouracil and its derivatives is due to poisoning by the monofluorinated organic metabolites, monofluoroaceticacid and a-fluoro b-alanine. Acta Neuropathol 1990; 81:66-73.
28. Askoy M, Basu T, Brint J, Dickerson JWT. Thiamine status of patients treated with drug combinations containing 5-fluorouracil. Eur J Cancer 1980; 16:1041-1045.